0000950170-24-042322.txt : 20240405 0000950170-24-042322.hdr.sgml : 20240405 20240405164530 ACCESSION NUMBER: 0000950170-24-042322 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240403 FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH IAN F CENTRAL INDEX KEY: 0001197032 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38360 FILM NUMBER: 24827095 MAIL ADDRESS: STREET 1: C/O ACORDA THERAPEUTICS, INC. STREET 2: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Solid Biosciences Inc. CENTRAL INDEX KEY: 0001707502 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 900943402 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 RUTHERFORD AVENUE STREET 2: 3RD FLOOR CITY: CHARLESTOWN STATE: MA ZIP: 02129 BUSINESS PHONE: 617-337-4680 MAIL ADDRESS: STREET 1: 500 RUTHERFORD AVENUE STREET 2: 3RD FLOOR CITY: CHARLESTOWN STATE: MA ZIP: 02129 FORMER COMPANY: FORMER CONFORMED NAME: Solid Biosciences, LLC DATE OF NAME CHANGE: 20170524 4 1 ownership.xml 4 X0508 4 2024-04-03 0001707502 Solid Biosciences Inc. SLDB 0001197032 SMITH IAN F C/O SOLID BIOSCIENCES INC. 500 RUTHERFORD AVENUE, THIRD FLOOR CHARLESTOWN MA 02129 true false false false false Common Stock 2024-04-03 4 M false 3256 A 103207 D Restricted Stock Units 2024-04-03 4 M false 3256 0 D Common Stock 3256 9765 D Restricted stock units convert into common stock on a one-for-one basis. The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. /s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith 2024-04-05